SPOTLIGHT: Pfizer's future rests with biotech


Here's an important note from the Bear Stearns Healthcare Conference: Expect to see Pfizer snapping up biologics from smaller drug developers and investing more money in biotech companies in the months and years to come. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.